 Spero Therapeutics Inc NASDAQ: SPRO has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to 125 million. Spero will use the proceeds to prepare for the anticipated launch of tebipenem HBr and support the continued clinical development of SPR720 and SPR206. 